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Muscle regeneration is essentially due to activation of satellite cells, which can be isolated and
amplified ex vivo, thus representing good candidates for cell therapy. Accumulating data show that
the local microenvironment plays a major role during muscle regeneration. In the satellite cell
niche, a major extracellular matrix protein is laminin. Human myoblasts transplanted into immun-
odeficient mice are preferentially located in laminin-enriched areas. Additionally, laminin-111
enhances myoblast proliferation in vitro and increases expression of the a7b1 integrin-type laminin
receptor. Intramuscular injection of laminin-111 ameliorates muscular pathology in mdx mice, pro-
tecting muscle fibers from damage. Moreover, transplantation of human myoblasts with laminin-
111 into Rag/mdx immunodeficient recipients improved efficacy of myoblast transplantation,
increasing the number of human dystrophin-positive myofibres. Taken together, these data strongly
indicate that exogenous laminin can ameliorate the regeneration process in different models of
muscular dystrophies and can be instrumental for improving cell therapy aiming at repairing the
degeneration/regeneration process in skeletal muscle.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction Mrf-4, essential for terminal differentiation, with the formationMuscle regeneration is essentially due to the activation of rare
unipotent muscular stem cells, called satellite cells (SC), which
are located in a specific niche, between the basement membrane
(BM) and the sarcolemma of muscle fibers [1]. After trauma or
injury, SC are activated, enter into the cell cycle, and undergo pro-
liferation. This initial proliferative phase is followed by differentia-
tion and muscle regeneration, which occurs by the fusion of
myoblasts either among themselves, forming new myotubes, or
fusing with existing damaged fibers. SC in healthy skeletal muscle
are quiescent and express the paired box protein Pax7. They also
express other surface markers such as c-met and CD56 (N-CAM)
[2,3]. Depending on the nature of the stimulus (trauma, injury or
diseases), the hepatocyte growth factor binds c-met and activates
the SC’s [4,5], which then upregulate their expression of Myf5
and MyoD, two of the myogenic regulatory factors (MRF)
expressed early after c-Met activation, and then myogenin andof post-mitotic multinucleated myotubes, although MRF-4 may
also play a role during development. These MRF induce the SC cells
to differentiate after the phase of proliferation. For example, MyoD
induces myoblasts to exit the cell cycle by enhancing the P21 tran-
scription factor, while myogenin triggers the expression of genes
involved in differentiation [6]. A sub-population of SC undergo
asymmetric division during the early phase of regeneration, and
will restore the pool of precursors [7]. Satellite cells are the only
progenitors physiologically able to regenerate adult skeletal mus-
cle after injury [8].
In this review, we will define the proliferating SC (expanded
in vitro or in vivo, after activation and before fused into myotubes)
as myoblasts. Given that these cells retain the muscular regenera-
tive capacity throughout the life span, and since they can be readily
isolated and amplified ex vivo, they have been envisioned as good
candidates for cell therapy: during muscle regeneration ex-vivo
repaired (autografts) or normal (allografts) cells may be inserted
into a dystrophic muscle to restore the missing protein (e.g. dys-
trophin in the case of Duchenne Muscular Dystrophy-DMD).
Although optimistic results were obtained by myoblast trans-
plantation in animal models, clinical trials, which started in the
90s, failed to show any clinical benefit. Despite the progress in
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years, no clear-cut benefits for the patients have been shown so
far [9,10], and improvements for cell therapy are necessary.
The fact that the injected myoblasts do not fulfill their expected
function efficiently when injected into patients, is an important
issue that needs to be explored. The results obtained from animal
models and in clinical trials using myoblasts as the cell source to
be grafted, have already highlighted some of the hurdles involved:
cell death, limited proliferation and migration of the transplanted
myoblasts, and the immune response against the donor cells in
allografts [2,11–13]. Interestingly, freshly isolated SC present a
much more efficient regenerative capacity than myoblasts ampli-
fied in culture [14]. Since in vitro amplification is necessary to
obtain the necessary numbers of cells prior to cell therapy,
improvement in cell culture conditions is essential [10].
The injection site where cells are to be transplanted also needs
to be considered in myoblast transfer therapy. Once transplanted,
myoblasts will be in contact with a local microenvironment that
is ultimately able to modulate their fate. Previous data show that
this microenvironment plays a major role during muscle regenera-
tion, by modulating the muscle progenitors and their interaction
with other cell types present during tissue regeneration. The mus-
cle microenvironment includes extracellular matrix (ECM) mole-
cules, secreted factors produced by either muscle progenitors
themselves, or differentiated/regenerating fibers, or also by non-
muscle cells such as fibroblasts and/or inflammatory cells present
in dystrophic or degenerating muscle. Cell fate, such as differenti-
ation versus proliferation, or self-renewal, will be the result of mul-
tiple interactions that will end up modifying the environment and
eventually the epigenetic status of the target cells. Modifications
observed in conditions such as aging or muscular dystrophy, dis-
turb the subtle balance between the cell compartments that ensure
proper tissue function and repair, leading to impaired regeneration
and fibrosis [15,16]. Considering the issues briefly discussed above,
it is obvious that improving the pre-transplantation culture and
injection conditions, as well as increasing our understanding of
the regenerative microenvironment where muscle differentiation
takes place, will provide essential clues to ameliorate the efficiency
of this strategy.
2. Laminin and basement membrane
LM is a major component of the BM and comprises a glycopro-
tein family with a cross-shaped structure. In vertebrates five alpha
(a) chains, three beta (b) chains and three gamma (c) chains have
been identified [17]. Alpha, beta and gamma chains combine to
form heterotrimeric isoforms, with a molecular weight between
400 and 900 Da. Presently, eighteen LM isoforms have been
described, although the in vivo existence of some of them still
needs to be confirmed [18]. These isoforms are named according
to their chain composition [19]: for example, the LM 111 (LM-
111) is composed of the a1, b1 and c1 chains.
Laminins are widely distributed throughout the body, mainly in
BM, playing important roles in tissue structure and maintenance,
cell signaling, adhesion, migration, among other functions
[20,21]. Each LM isoform is differently expressed in the body. For
instance, LM-211 and LM-221 have been identified in the neuro-
muscular system, whereas LM-332 is the most abundant isoform
in the skin. LM isoforms containing a4 chain are the major isoform
present in the BM of blood vessels and the isoforms-containing a5
chains are widely distributed through the body. LM-111, despite
being the most studied isoform, is restricted in adults to some
epithelial BM [22].
In the skeletal muscle tissue, LM short arms essentially play a
structural role, interacting with other LM short arms, thus creatinga network where type IV collagen binds LM via entactin/nidogen,
thus structuring the muscular BM. Adhering to this initial BM,
other ECM components, such as collagens and proteoglycans, will
form the interstitial matrix [23]. The long arm of the LM cross is
an a-helical coiled coil structure composed of the three chains.
The C-terminal part of the a chain extends into the long arm and
has 5 LM G-like domains, representing a very important binding
site for cell surface receptors. Cell–LM interactions are mediated
by integrin-type as well as non-integrin receptors, including dys-
troglycan, syndecans and lutheran blood group glycoprotein. The
integrins a1b1, a2b2, a3b1, a6b1, a6b4, a7b1, a9b1, avb3, aMb2
are known to bind LM, and most of them recognize the globular
domain of the long arm [20,22,24]. However, only four of these
integrins are considered to be highly selective LM receptors:
a3b1, a6b1, a6b4 and a7b1 [25–27].
3. Laminin in normal skeletal muscle and regeneration
As mentioned above, LM are major BM components, and LM-
211 and LM-222 are the main isoforms present in adult skeletal
muscle, linking muscle fibers and SC to other BM components
such as collagens, glycoproteins, proteoglycans and glycosamino-
glycans [23]. LM-211 is located within the BM that surrounds the
sarcolemma, whereas LM-221 predominates in the neuromuscu-
lar and myotendinous junctions [28]. The importance of these
a2-containing LM isoforms is emphasized by the fact that
mutations in the a2 LM chain causes severe congenital muscular
dystrophies in both humans and animals [29]. The muscle fiber
binds to LM via two major receptors: b-dystroglycan [30] and
the integrin a7b1 [31]. During skeletal muscle regeneration, LM
isoforms in addition to LM-211 and LM-221 are also expressed.
For example during the regenerative process induced by crush
injury in normal and in dy/dy mice (a mouse model for the LM
alpha 2 mutation), a4 and a5 LM chains are transiently
expressed in the BM of small diameter myofibers (that corre-
spond to the newly regenerated muscle fibers), suggesting their
involvement in early myogenic differentiation. a4 and a5 LM
chains are also present during the early fusion process [32] in
regenerating muscles of BALB/c mice. Alpha-7 integrin chain
can also be detected in myoblasts and newly formed myotubes.
In the dy/dy mouse, a6 integrin chain is also detected in the
newly formed myotubes [33].
In DMD patients and in mdx mice (the mouse model for DMD)
a7 integrin chain is upregulated, while the levels of this molecule
are reduced in patients with LM a2 chain congenital muscular dys-
trophy and in dy/dy mice [34]. The increase in a6 integrin chain
observed in the newly formed myotubes of dy/dy mice may poten-
tially compensate the decrease in a7 or the absence of a2. More-
over transgenic overexpression of a7 integrin chain in a2 LM
chain deficient mice reduces muscle pathology [35]. These results
indicate that although LM-211 and the integrin a7 (together with
the dystroglycan complex) predominate in the BM of muscle fibers,
other LM isoforms and other integrins are modulated during regen-
eration, suggesting that these molecules also play a relevant role
during muscle repair.
4. Laminin in myoblast transplantation
In an ideal configuration for cell therapy to ensure efficient
repair, the transplanted myoblasts will survive, proliferate and
migrate substantially before differentiating and ultimately regen-
erate the damaged muscle. In addition, a pool of ‘‘healthy” SC must
be created to ensure ‘‘future” cycles of regeneration. Since LM can
protect different cell types from death, promote proliferation and
migration and influence differentiation, the various LM isoforms
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therapy for muscular diseases.
Using a model where human myoblasts were transplanted into
damaged and/or irradiated tibialis anterior muscle of immunodefi-
cient mice, we demonstrated that injected myoblasts were prefer-
entially located in LM-enriched areas. The regenerative capacity of
human myoblasts transplanted into irradiated and cryodamaged
muscles was higher, as compared to muscles that were only cryo-
damaged. Local irradiation increased muscular LM deposition, as
well as the number of donor cells and most importantly, the num-
ber of human fibers one month after transplantation [36]. More
recently, we showed that LM (detected with a polyclonal antibody
that does not discriminate a particular isoform) is present at the
site where human myoblasts were injected into damaged tibialis
anterior muscle as early as the first hours after transplantation,
forming ‘‘pocket-like” structures where transplanted cells were
concentrated. This expression was increased as a function of time
post-transplantation [13]. However, despite the increase of LM
deposition within these pockets, the proliferation rate decreased
and cell migration stopped as early as 3 days post-injection, a time
point when differentiation was observed, indicating that the LM
present around the cells was not sufficient to stimulate the prolif-
eration and dispersion of the injected human myoblasts.
As discussed above, the major hurdles hampering the success of
myoblast transplantation are a rapid cell death, a low proliferation
of the transplanted cells and, possibly linked to the former, a
reduced migration within the host’s tissue [11,37]. LM can trigger
cellular signals, potentially influencing processes such as survival,
proliferation and migration [22,38]. This is also true concerning
SCs and myoblasts: LM stimulates cultured myoblasts to survive,
proliferate and migrate [36,39–44].
5. Exogenous LM treatment improves muscle regeneration and
efficiency of myoblast transplantation
In vitro, treatment with LM-111 increased a7 integrin expres-
sion in murine and human DMD patient myoblasts. Moreover,
intramuscular injection of LM-111 increased a7 integrin in muscle
fibers and ameliorated the dystrophic phenotype in mdx mice. LM
a1 chain was still detected in the BM of muscles from mdx mice
28 days after intra-peritoneal injection of this isoform in ten-day-
old mdx pups. This systemic LM-111 treatment resulted in an
important reduction in serum creatine-kinase levels in mdx mice
after 3 weeks [45]. It was also demonstrated that both intramuscu-
lar and intraperitoneal LM-111 injection protected muscle fibers of
mdx mice from damage induced by eccentric contractions [40].
Finally, the transplantation of human myoblasts with LM-111 in
tibialis anterior muscles of Rag/mdx mice improved the efficiency
of myoblast transplantation, with more human dystrophin-
positive myofibers 24 days after grafting [40].
When a large number of, myoblasts are injected, concentrated
within adapted medium, they cannot anchor with ECM, and this
may lead to anoikis, a programmed cell death secondary to cell dis-
placement from ECM [46]. Human myoblasts cultured in condi-
tions preventing adhesion showed an important percentage of
apoptotic cells (anoikis), and the addition of fibronectin diminished
significantly this percentage. When human myoblasts were
injected together with fibronectin in immunodeficient mice, the
presence of this molecule significantly increased the survival of
injected cells as compared to those injected without fibronectin
[47]. This raises the hypothesis that injection of myoblasts with
LM may also somehow nurse the cells in the first hours after trans-
plantation, although this still needs to be demonstrated.
Treating a2 LM chain deficient (dyw) mice with LM-111
resulted in a reduction of the muscle pathology, in parallel withan increased lifespan. The injected LM-111 isoform could be iden-
tified within the ECM surrounding the muscle fibers. One possible
mechanism explaining the positive effect of LM is apoptosis reduc-
tion, since TUNEL-positive muscle nuclei were decreased in LM-
111 treated animal when compared to the group treated with
PBS. Interestingly, primary myogenic cells isolated from a2 LM
(also called merosin) deficient congenital muscular dystrophy type
1A (MDC1A) patients, presented a reduced apoptosis when treated
with murine or human LM-111, indicating that the LM-111 effect is
conserved between mouse and human [48]. The same group also
observed that an improved regeneration of the muscles of dyw
mice was observed after injection of LM-111 (with an increase in
numbers and size of myofibers), resulting in enhanced expression
of myogenin, embryonic myosin heavy chain and a7b1 integrin,
and overall an improvement of muscle regeneration [49].
a7 integrin chain deficient mice present defective muscle
regeneration and a reduced expression of a2 LM chain in the BM
of their muscle fibers [50]. In these animals, a1 LM chain could
be detected surrounding the muscle fibers after LM-111 treatment,
which restored muscle regeneration [51].
It is important to note that LM treatment can also influence
other cell types distinct from muscular progenitors. LM-111 treat-
ment, 1 week before eccentric exercise, resulted in an increase in
the number of proliferating SC, but also in a decrease in gene
expression of proinflammatory cytokines by muscle-derived mes-
enchymal stem cells [52].
6. Conclusions and perspectives
The data summarized above strongly indicating that LM plays a
role in the survival, proliferation and dispersion of transplanted
human myogenic precursors suggest that manipulation of LM-
mediated interactions can be envisaged as a strategy for improving
cell therapy in skeletal muscle degeneration/regeneration pro-
cesses, as illustrated in Fig. 1. However, a detailed knowledge of
which myogenic precursor-derived genes are transcribed or
repressed along with or because of such interactions are lacking,
and a better understanding of the complex signaling underlying
this whole process, including identifying parameters involved in
the progression of the dystrophic process, which in turn may rep-
resent therapeutic targets, is essential.
Another important issue to consider is the large variety of LM
isoforms. So far, only LM-111 has been applied in cell therapy pro-
tocols in regenerating skeletal muscle tissue, and we do not know
if other isoforms may be more efficient than LM-111. Knowing
which LM isoforms are expressed over time following myoblast
transplantation would be instrumental, in order to better design
experiments using other isoforms as adjuvant in myoblast therapy
experiments.
Both cell and gene therapy approaches are hampered by the dif-
ficulty to reach the targets within a dystrophic and fibrotic tissue,
and a modified LM network may play a relevant role in these pro-
cesses. We hypothesize that disturbances in the complex signaling
networks regulating LM are involved, at least partly, in the devel-
opment of fibrosis, which is a major pathological event in the evo-
lution of muscle dystrophies, and which gradually blocks access to
or dispersion of transplanted cells applied as a therapeutic
strategy.
In terms of translating the experimental data into therapeutic
protocols to be applied in humans, a further important step to
overcome is the immune response of the host. As we described
above, in human-mouse xenograft models used for transplanting
human myogenic precursors, the recipients are immunodeficient
animals, unable to elaborate a cell-mediated immune response.
In mouse/mouse models, isogeneic transplantation conditions are
Fig. 1. Hypothetical role of laminin as a therapeutic co-factor for improving cell therapy in muscular lesions. The diagram shows in A the fate of the transplanted myogenic
precursors after injection⁄. Among the population of transplanted myoblasts (blue cells), many cells die, but some proliferate. At later time points after transplantation,
proliferation decreases, as well as cell death. Cells reach proliferative arrest and differentiation, correlated with a poor dispersion. In line B we hypothesize that co-injection of
myoblasts with laminin (LM) may enhance early myoblast survival in the first hours post-engraftment, probably avoiding anoikis. LM can also increase proliferation and
migration, and consequently delay myoblast differentiation, which will result in bringing a therapeutic effect to a larger area of the damaged muscle. *Line A was based on Ref.
[12].
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Ongoing experiments in our laboratory indicate that we can induce
immunological tolerance to human myoblast antigens in immuno-
competent recipients. This will hopefully allow us to further study
the expression and role of LMs in pre-clinical settings for cell ther-
apy aiming to regenerate skeletal muscle in humans.
Despite the promising effects of exogenous LM in experimental
animal models of muscular diseases, alone or as co-adjuvant in cell
therapy, some aspects need to be taken into account before trans-
lating this approach for patients. A source for clinical grade purified
laminin has to be defined: LMs can be produced as recombinant
proteins, but since they are large (LM-111 has around 900 kd)
and heterotrimeric, their large scale production may represent a
technological as well as an economic challenge.
Another issue to be taken into consideration is the putative
immune reaction against the LM applied. In the papers we have
discussed, the LM used for therapy was the natural LM-111 puri-
fied from Engelbreth–Holm–Swarm mouse sarcoma cells. In some
studies, this LM was incorporated in the BM of muscle fibers
1 month after treatment [51,49,45], indicating the absence of an
adaptive immune response against the molecule, but more
detailed studies are required. As an alternative strategy LM-
derived peptides or fragments could be used, since they are easy
to be isolated and produced, potentially much less immunogenic,
and their potential has been documented [53,54], although not in
terms of clinical benefit: an intact LM molecule may be necessary
to restore the BM structure.
In conclusion, further understanding of the LM biology in mus-
cle regeneration, together with the definition of which are the con-
ditions to optimize its usage in cell therapy for skeletal muscle,
represent new challenges to be overcome.
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